

Special Issue

Drug Repurposing in Cancer Treatment and Impacting the Efficacy of Therapeutic Agents

Message from the Guest Editor

Cancer treatment remains an ongoing challenge, especially those malignancies which develop resistance to conventional therapeutic agents. While several tumor resistance mechanisms have been identified and strategies to overcome such mechanisms have resulted in improved responses of therapeutic agents, the overall survival benefits remain relatively low. Thus, new approaches to target those counter-regulatory pathways involved in impeding the efficacy of cancer therapy are being implicated to improve cancer treatment. Drug repurposing explores the use of existing investigational drugs with the known mechanisms of action for new clinical purposes, such as the treatment of human malignancies. There is an increased interest in exploring the potential of drug repurposing either alone, or in combination with conventional anticancer agents for cancer treatment. The focus of this Special Issue is to publish original research or review articles related to drug repurposing for cancer treatment, or improving the efficacy of therapeutic agents, including targeted therapy. Articles exploring the effectiveness of any drug repurposing candidates on any cancer models will be considered.

Guest Editor

Dr. Ravi P. Sahu

Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, Fairborn, OH 45324, USA

Deadline for manuscript submissions

closed (31 October 2024)



Medical Sciences

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/125294

Medical Sciences
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
medsci@mdpi.com

mdpi.com/journal/

[medsci](https://mdpi.com/journal/medsci)





Medical Sciences

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
medsci](https://mdpi.com/journal/medsci)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Antoni Torres

1. Institut D investigacions August Pi I Sunyer (IDIBAPS), Department of Pulmonology, Hospital Clinic de Barcelona, Universidad de Barcelona, 08036 Barcelona, Spain

2. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, MEDLINE, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.7 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).